Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Cost of Revenue (2016 - 2024)

Historic Cost of Revenue for Regenxbio (RGNX) over the last 11 years, with Q4 2024 value amounting to $6.3 million.

  • Regenxbio's Cost of Revenue fell 4378.0% to $6.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $33.6 million, marking a year-over-year decrease of 979.77%. This contributed to the annual value of $33.6 million for FY2024, which is 979.77% down from last year.
  • Latest data reveals that Regenxbio reported Cost of Revenue of $6.3 million as of Q4 2024, which was down 4378.0% from $12.4 million recorded in Q3 2024.
  • In the past 5 years, Regenxbio's Cost of Revenue ranged from a high of $23.1 million in Q4 2021 and a low of $3.4 million during Q1 2020
  • Its 5-year average for Cost of Revenue is $10.6 million, with a median of $10.9 million in 2023.
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 1165517.24% in 2020, then plummeted by 7383.72% in 2023.
  • Over the past 5 years, Regenxbio's Cost of Revenue (Quarter) stood at $10.3 million in 2020, then skyrocketed by 124.8% to $23.1 million in 2021, then tumbled by 44.56% to $12.8 million in 2022, then decreased by 12.09% to $11.2 million in 2023, then tumbled by 43.78% to $6.3 million in 2024.
  • Its Cost of Revenue stands at $6.3 million for Q4 2024, versus $12.4 million for Q3 2024 and $10.6 million for Q2 2024.